Navigation Links
Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
Date:6/28/2011

HAYWARD, Calif., June 28, 2011 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced  today the presentation of final 48-week results of a phase 2 clinical study of ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) for the treatment of type 2 diabetes at the American Diabetes Association's 71st Scientific Sessions in San Diego, California.

(Logo:  http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

Results of the phase 2 study, presented by Julio Rosenstock, M.D., Director of the Dallas Diabetes and Endocrine Center at Medical City and Clinical Professor of Medicine at the University of Texas Southwestern Medical School, demonstrated that patients receiving treatment with ITCA 650 experienced substantial and sustained reductions in HbA1c, fasting plasma glucose (FPG) and body weight during the 48 weeks of treatment at all doses. A starting dose of ITCA 650 20 mcg/day for weeks 1 through 12 provided improved glycemic control with the best tolerability profile. Subsequent transition to ITCA 650 doses of 40, 60 or 80 mcg/day led to statistically significant improvements in HbA1c, FPG and body weight after 24 and 48 weeks of treatment.  

"We are very encouraged by the robust results observed in this study and the high level of enthusiasm expressed by patients and investigators," said Kurt Graves, Executive Chairman of the Board of Directors of Intarcia. "ITCA 650 is a novel GLP-1 therapeutic approach for type 2 diabetes that holds new promise for many patients and physicians who want robust glucose reductions and a favorable weight profile without the trade-offs associated with having to start potentially life-long and frequent self-injections." Graves added, "ITCA 650 not only delivers sustained glycemic control and favorable weight effects but the breakthrough subcutaneous continuous delivery platform is being developed as just a once-
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
2. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
3. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
8. SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use
9. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
10. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
11. TGen and PBS-Bio presents 2 abstracts at AACR conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Tris Pharma, a specialty pharmaceutical company ... that it has been selected as an award winner ... 2014 Awards for Excellence competition in the Business ... of judges from SCORE (Counselors to America,s Small Business) ... honored at a gala event to be held on ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... stands to reason that the next beverage craze is ... Technology announced today that formulators can use Stress Relief ... ingredient used in the making of a beverage, including ... release for stress-generated energy, channeling that power into rapid ...
(Date:8/27/2014)... Cranford, NJ (PRWEB) August 27, 2014 ... and services – has once again shown superiority when ... trial sponsor by completing the ePRO portion of their ... results. The Japan-based pharma chose WriteResult’s digital writing ... IBS trials – the first to complete drew data ...
(Date:8/26/2014)... LOS ANGELES , Aug. 26, 2014  NeuroSigma, ... sciences company established to develop bioelectronic technologies, today announced ... S-1 with the U.S. Securities and Exchange Commission relating ... stock. The number of shares to be offered and ... yet been determined. Jefferies LLC will act ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Colo., Sept. 24 InVitria,( http://www.InVitria.com ) ... "Optimizing Cell Culture Development" Conference on,September 15-16 ... recent,results optimizing cell culture media using its ... http://www.healthtech.com/ocb/overview.aspx?c=562 ), In a presentation of ...
... use of AHCC for immune enhancement during cold & ... new paper published in,Nutrition Reviews (Vol. 66(9):526-531) by Dr. ... Drexel University, has shown,how AHCC impacts the immune response ... review analyzed outcomes from in vivo studies evaluating,the effect ...
... Calif., Sept. 24 NeurogesX, Inc.,(Nasdaq: NGSX ... novel pain management therapies, announced today that it,has ... (EMEA) Day 120,questions to support the Marketing Authorization ... NeurogesX, MAA for NGX-4010 in peripheral neuropathic pain ...
Cached Biology Technology:InVitria Touts Product Advantages at Cambridge's Cell Culture Conference 2Research Shows How AHCC(R) May Help Fight Flu and Other Infectious Agents 2NeurogesX Responds to EMEA's Day 120 Questions 2NeurogesX Responds to EMEA's Day 120 Questions 3
(Date:8/27/2014)... 400 million years ago a group of fish began exploring ... and mammals. But just how these ancient fish used their ... evolutionary processes were at play remain scientific mysteries. , ... , turned to a living fish, called Polypterus , ... attempted to walk out of the water. Polypterus ...
(Date:8/27/2014)... brain of mice, scientists have altered the emotional ... Howard Hughes Medical Institute investigator Susumu Tonegawa at ... the connections between the part of the brain ... the part of the brain that stores the ... , Altering those connections can transform a negative ...
(Date:8/27/2014)... greatest risk to Europe based upon a proxy for ... using a ,big data, approach to scientific research. , ... Global Health ranked the top 100 pathogens affecting humans ... system which, they believe, will help governments across the ... infectious diseases, including as a result of climate change, ...
Breaking Biology News(10 mins):Walking fish reveal how our ancestors evolved onto land 2Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2
... 12, 2009) HOBOKEN, NJ According to the ... U.S. population will have hemorrhoids by the age of ... hemorrhoids is over-the-counter remedies, most patients do not report ... they are in severe distress, including bleeding. A ...
... A growing number of scientists are merging methods and results ... says a team of researchers in a recent issue of ... focused on new data, however, researchers who want to analyze ... institutional support, the authors say. In a commentary piece in ...
... - Mango. If you know little about this fruit, understand ... and breast cancer cells in the lab. That,s ... scientists, who examined the five varieties most common in the ... the mango is an ancient fruit heavily consumed in many ...
Cached Biology News:Study shows pine bark naturally relieves symptoms of acute hemorrhoids 2Study shows pine bark naturally relieves symptoms of acute hemorrhoids 3Biologists merge methods, results from different disciplines to find new meaning in old data 2Biologists merge methods, results from different disciplines to find new meaning in old data 3Mango effective in preventing, stopping certain colon, breast cancer cells 2
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z35,347-7) or contact ...
... Freedom EVO384R are fast multi-channel pipetting platforms ... different sizes, with a multi-channel head and ... time saving, with true parallel processing of ... your assays with the Freedom EVOware program. ...
... EVO384R are fast multi-channel pipetting platforms consisting ... sizes, with a multi-channel head and a ... saving, with true parallel processing of sample ... assays with the Freedom EVOware program. ...
Prepared by multi-temperature ethanol fractionation with extensive charcoal treatment and dialysis.• Assay: ≥ 95 % (HPCE)• pH ~5.2 (10 mg/mL in 0.15 M NaCl)...
Biology Products: